FibroGen, Inc. Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals With Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update
Published: May 03, 2012
SAN FRANCISCO--(BUSINESS WIRE)-- FibroGen, Inc., today announced expansion of an ongoing open-label Phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF). The company’s decision to add a second, higher dose group is based on promising preliminary data from the first dose group as well as dose-escalation data from other clinical trials of FG-3019 indicating that higher doses of FG-3019 appear to be associated with a more robust biological and clinical response. FibroGen has also decided to add on another year of FG-3019 therapy for patients in the first dose group who are exhibiting stable or improved lung function in order to evaluate whether the observed maintenance of lung function continues.